Related Experiment Video
Updated: Aug 3, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy
Vanessa Ibrahim1, Catherine Isroff1, Christopher D Stephen1
1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Background:
The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed.
Objectives:
To evaluate the MoCA as an outcome measure in PSP clinical trials.
Methods:
Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation.
Results:
There was a significant decline in the MoCA score over time of -1.4 (95% CI -0.84 to -1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (r rm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (r rm = -0.25, p < 0.0001).
Conclusion:
The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.
Related Concept Videos
Stereotypes, Prejudice, and Discrimination
¹H NMR Signal Integration: Overview
Multiple Comparison Tests
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)
McNemar's Test
Halo Effect

